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A bs tr ac t
Background
The use of prescription opioid medications has increased greatly in the United 
States during the past two decades; in 2010, there were 16,651 opioid-related deaths. 
In response, hundreds of federal, state, and local interventions have been imple-
mented. We describe trends in the diversion and abuse of prescription opioid anal-
gesics using data through 2013.
Methods
We used five programs from the Researched Abuse, Diversion, and Addiction- 
Related Surveillance (RADARS) System to describe trends between 2002 and 2013 
in the diversion and abuse of all products and formulations of six prescription opi-
oid analgesics: oxycodone, hydrocodone, hydromorphone, fentanyl, morphine, and 
tramadol. The programs gather data from drug-diversion investigators, poison cen-
ters, substance-abuse treatment centers, and college students.
Results
Prescriptions for opioid analgesics increased substantially from 2002 through 2010 
in the United States but then decreased slightly from 2011 through 2013. In gen-
eral, RADARS System programs reported large increases in the rates of opioid di-
version and abuse from 2002 to 2010, but then the rates flattened or decreased from 
2011 through 2013. The rate of opioid-related deaths rose and fell in a similar pat-
tern. Reported nonmedical use did not change significantly among college stu-
dents.
Conclusions
Postmarketing surveillance indicates that the diversion and abuse of prescription 
opioid medications increased between 2002 and 2010 and plateaued or decreased 
between 2011 and 2013. These findings suggest that the United States may be mak-
ing progress in controlling the abuse of opioid analgesics. (Funded by the Denver 
Health and Hospital Authority.)
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Whatever the measure, the past two decades have been characterized by increasing abuse and diversion of pre-
scription drugs, including opioid medications, in 
the United States. An estimated 25 million peo-
ple initiated nonmedical use of pain relievers be-
tween 2002 and 2011.1 The number of deaths per 
year attributed to prescription opioid medications 
reached 16,651 in 2010.2 In response to the epi-
demic, hundreds of local, regional, state, and 
federal interventions have been implemented. 
For example, 49 states have enacted legislation to 
create prescription-drug monitoring programs.3 
The U.S. Office of National Drug Control Policy 
has responded to the epidemic with numerous 
recommendations, including the need to evaluate 
“current databases that measure the extent of 
prescription drug use, misuse, and toxicity.”4 In 
2013, a Pew Research Center survey showed that 
only 16% of Americans believed that the United 
States was making progress in reducing prescrip-
tion-drug abuse.5
The impressive response to the epidemic is 
heartening, but the effect of these programs is 
not yet known. Some local and state interven-
tions have described a reduction in the abuse 
and diversion of prescription opioids after the 
enactment of state legislation.6,7 We used the 
Researched Abuse, Diversion, and Addiction-
Related Surveillance (RADARS) System to describe 
the diversion and abuse of prescription opioid 
analgesics, using data from January 2002 through 
December 2013. Because drug abuse is an illegal 
activity that is often concealed from authorities, 
the RADARS System uses a “mosaic” approach, 
measuring abuse and diversion from multiple 
perspectives, to describe this hidden phenome-
non as comprehensively as possible.8
Me thods
Data Sources and Oversight
We used data from five separate RADARS System 
programs (Table 1). The Poison Center Program 
records the substances involved in poison-center 
cases classified as intentional abuse. The Drug 
Diversion Program records the drugs involved in 
cases opened by law-enforcement agencies inves-
tigating prescription-drug diversion. The Opioid 
Treatment Program and the Survey of Key Infor-
mants’ Patients (SKIP) Program query new pa-
tients entering substance-abuse treatment about 
medications that they have abused in the previous 
30 days. The College Survey Program is a Web-
based survey in which self-identified college stu-
dents report their nonmedical use of prescription 
drugs during the previous 30 days. Further infor-
mation on each program is provided in Table 1, 
the Supplementary Appendix (available with the 
full text of this article at NEJM.org), and previous 
publications.9-13 Several analyses describe the 
relations among these programs and other in-
formation sources such as the Drug Abuse 
Warning Network and the National Vital Statis-
tics System.10,14
To represent the trends with respect to pre-
scription opioid analgesics, we grouped all mar-
keted products and formulations (branded and 
generic) of six prescription analgesics: oxycodone, 
hydrocodone, hydromorphone, fentanyl, mor-
phine, and tramadol. More recent market entrants 
with smaller market shares (e.g., oxymorphone 
and tapentadol) were excluded so that the trend 
analysis involved a consistent profile of analge-
sics. Sensitivity analyses showed that the results 
were not materially affected by the exclusion of 
these products. In addition, we retrieved data on 
reported heroin use in the past 30 days in the 
Opioid Treatment, SKIP, and College Survey Pro-
grams. (Not all programs include heroin because 
the RADARS System focuses on prescription opi-
oids.) Because the RADARS Poison Center Pro-
gram does not collect data on heroin, we obtained 
counts of heroin-related cases from the National 
Poison Data System (American Association of 
Poison Control Centers) and data on reported 
heroin use in the past 30 days (National Survey 
on Drug Use and Health).15,16 Data on prescription 
volume were obtained from IMS Health.17
The RADARS System is independently owned 
and operated by the Denver Health and Hospital 
Authority, which operates the public hospital for 
the city and county of Denver. The system is sup-
ported by subscriptions from pharmaceutical 
companies that produce prescription opioids or 
stimulants, which use the data for risk manage-
ment and postmarketing surveillance reporting 
to the Food and Drug Administration. Subscrib-
ers had no role in the conception, execution, or 
reporting of this analysis. Each program in the 
RADARS System is approved by the institutional 
review board of the principal investigator’s insti-
tution (Tables S1 through S6 in the Supplemen-
tary Appendix).
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on February 4, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
Opioid Analgesic Abuse in the United States
n engl j med 372;3 nejm.org january 15, 2015 243
Statistical Analysis
We plotted the quarterly event rate by dividing 
the total number of events for the prescription-
opioid group for each program by the population 
of the jurisdiction or coverage area of the pro-
gram. Population data were obtained from the 
2000 and 2010 U.S. Census at the level of the 
three-digit ZIP Code. Interpolation and extra-
polation at this level adjusted for population 
changes over time. Because the plots were sug-
gestive of a second-degree polynomial fit, we 
used a Poisson regression model with linear and 
quadratic terms for time. Quadratic and cubic 
models were evaluated, and the quadratic model 
was chosen because it fit the largest number of 
programs. We computed the time of the maxi-
mum predicted value (vertex) of the curve, which 
indicates when the population rate changed from 
an increasing to a decreasing trajectory. A nega-
tive quadratic coefficient indicates that the qua-
dratic curve is concave (with the apex at the top 
and the curve opening downward). The t-statistic 
was used to test whether the quadratic coeffi-
cient differed from zero. A significant result in-
dicates that the quadratic term provided a better 
fit to the data than the linear term. 
R esult s
Trends in Opioid Analgesic Use
Prescription data from IMS Health indicate that 
at the beginning of 2006, there were 47 million 
prescriptions dispensed per quarter in the United 
States for the opioid analgesics included in this 
study. Prescription volume peaked in the fourth 
quarter of 2012 at 62 million prescriptions dis-
pensed. Except for this one quarter, the number 
of prescriptions trended slightly downward from 
2011 through 2013, ending at 60 million pre-
scriptions per calendar quarter for study medica-
tions (Fig. 1A).
In the Drug Diversion Program, the calculat-
ed quarterly event rate for prescription opioids 
increased from approximately 1.5 per 100,000 
population in 2002 to 2.9 in 2012 and then de-
creased to 2.5 by the end of 2013 (Fig. 1B). In 
the Poison Center Program, the quarterly abuse 
rate for opioid analgesics increased from 0.20 
per 100,000 population in 2003 to 0.56 in 2010 
and then decreased to 0.35 by the end of 2013 
(Fig. 1C). In the Opioid Treatment Program, the 

































































































































































































































































































































































































































































































































































































































































































































































































The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on February 4, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e

















































































































































































































































































































































































































































































E Survey of Key Informants’ Patients Program
Figure 1. Prescriptions Dispensed for Opioid Analgesics and Rates of Abuse and Diversion, RADARS System, 2002–2013.
Data are displayed according to calendar quarter. Panel A shows the number of prescriptions dispensed for the opioid analgesics includ-
ed in the analysis (IMS Health). Panel B shows the rate of drug-diversion cases opened. Panel C shows the rate of cases of intentional 
abuse reported to participating poison centers. Panel D shows the rate of reported abuse by persons entering methadone programs. 
Panel E shows the rate of reported abuse by patients entering other substance-abuse treatment programs. Panel F shows the rate of re-
ported nonmedical opioid use by college students. The red boxes in Panels B through E indicate the vertex of the quadratic curve. (There is 
no red box in Panel F because the quadratic terms were not significant; Panel A is provided for context and was not part of the planned 
analysis.) Details of the data-collection procedure and case definition are provided in the Supplementary Appendix. RADARS denotes 
Researched Abuse, Diversion, and Addiction-Related Surveillance.
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1.6 per 100,000 population in 2005 to 7.3 in 
2010 and then decreased to 3.5 by the end of 
2013 (Fig. 1D). In the SKIP Program, the rate of 
prescription opioid abuse increased from 1.5 per 
100,000 population in 2008 to 3.8 in 2011 and 
then decreased to 2.8 by the end of 2013 (Fig. 
1E). In the College Survey Program, the rate of 
nonmedical use increased from 0.14 per 100,000 
population in 2008 to 0.35 by the end of 2013 
(Fig. 1F). Using a Poisson regression model, we 
found that the quadratic coefficient was negative 
and significantly different from zero in the 
Poison Center Program (P<0.001), the Drug 
Diversion Program (P = 0.009), the Opioid Treat-
ment Program (P<0.001), and the SKIP Program 
(P = 0.001). Before mid-2010, the rate of diversion 
or abuse was increasing in each program; how-
ever, the rate in each program trended down-
ward by 2013. The only exception was the Col-
lege Survey Program, in which the quadratic 
term was not significant (P = 0.41).
Reported heroin use generally increased over 
time. In poison centers, as evidenced by data 
from the National Poison Data System, the rate 
of heroin-related cases started increasing in 
2006 and appeared to accelerate in late 2010 
(Fig. 2A). In conjunction with increasing heroin 
use, cases involving the extended-release formu-
lation of oxycodone (OxyContin, Purdue Pharma) 
decreased substantially after the introduction of 
an abuse-deterrent formulation (Fig. 2A). In the 
Opioid Treatment Program, the rate of heroin 
use was flat for the period from 2005 through 
2013, and the rate of abuse of reformulated ex-
tended-release oxycodone decreased after 2010 
(Fig. 2B). In the SKIP Program, the rate of heroin 
use increased in 2011 and remained increased, 
whereas the rate of abuse of reformulated ex-
tended-release oxycodone decreased (Fig. 2C). In 
the College Survey Program, the rate of heroin 
use was volatile but generally flat, whereas the 
rate of abuse of reformulated extended-release 
oxycodone edged upward (Fig. 2D). Reported use 
of heroin increased after 2005 in the National 
Survey on Drug Use and Health (Fig. 2E).
Opioid-Related Deaths
The rate of death associated with heroin use 
(data from the National Poison Data System) was 
inversely related to the rate of death associated 
with the use of prescription opioid drugs. The 
rate of opioid-related death increased from 2002 
to 2006, plateaued from 2006 through 2008, 
then decreased slightly from 2009 through 2013 
(Fig. 3). In contrast, the rate of heroin-related 
death was flat from 2002 to 2010 but increased 
each subsequent year through 2013.
Discussion
Our results show a parallel relationship between 
the availability of prescription opioid analgesics 
through legitimate pharmacy channels and the 
diversion and abuse of these drugs and associated 
adverse outcomes. Availability increased greatly 
in the 1990s and continued through 2010 but 
then plateaued from 2011 through 2013. In con-
cert with these findings, four of five RADARS 
System surveillance programs reported large in-
creases in diversion and abuse from 2002 to 
2010. An inflection point was reached in each 
program, however, and the rates of diversion and 
abuse of prescription analgesics subsequently de-
creased.
For the period before 2011, our results are 
similar to those in other research reports, with 
increasing rates of opioid analgesic abuse. The 
Drug Abuse Warning Network reported an in-
crease of 183% in medical emergencies related 
to opioid pharmaceuticals from 2004 to 2011, 
the last year for which data are available.18 The 
National Survey on Drug Use and Health noted 
increasing dependence on and abuse of prescrip-
tion pain relievers from 2002 through 2012, the 
last year for which data are available.19 Similarly, 
admissions for the treatment of opioid depen-
dence and addiction increased through 2011.20 
These increases in drug availability and abuse 
have been reflected in the numbers of deaths 
caused by prescription opioids, which increased 
for 11 consecutive years and reached 16,651 
deaths nationally in 2010.2
Few data regarding national trends in pre-
scription-drug abuse and diversion since 2010 
have been published. However, emerging data 
suggest that abuse of prescription opioids may 
have lessened in some environments. For exam-
ple, local and state efforts have resulted in a 
reduction after the enactment of state legisla-
tion.6 Florida had a substantial decrease in the 
diversion of prescription analgesics, especially 
oxycodone, after several interventions were im-
plemented in 2010 and 2011.7 Reported prescrip-
tion-drug abuse was also reduced in a study 
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involving college students.21 In contrast, the 
prevalence of nonmedical use of prescription 
analgesics remained unchanged in the National 
Survey on Drug Use and Health through 2012.19
The observed trends in opioid analgesic abuse 
could be related to several factors. The flatten-
ing rate of prescription volume since 2011 may 
have limited the availability of prescription opi-
OxyContin Heroin


















































































































































































































































































































































































































































































































Figure 2. Rates of Heroin Use and OxyContin Abuse before and after OxyContin Reformulation.
Data are displayed according to calendar quarter and in relation to the release of reformulated OxyContin in August 2010 (vertical line in 
each panel). Panel A shows data for heroin use (National Poison Data System, American Association of Poison Control Centers) and in-
tentional abuse of OxyContin (RADARS Poison Center Program). Panel B shows the rate of reported heroin use and OxyContin abuse by 
patients entering the RADARS Opioid Treatment Program. Panel C shows the rate of reported heroin use and OxyContin abuse by pa-
tients entering the RADARS Survey of Key Informants’ Patients Program. Panel D shows the rate of reported heroin use and OxyContin 
abuse in the RADARS College Survey Program. Panel E shows the rate of reported heroin use in the National Survey on Drug Use and 
Health (Substance Abuse and Mental Health Services Administration).
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oids for abuse. This trend may be evidence of 
either a decreased supply, because prescribers 
have reduced the number of prescriptions that 
they write, or a decreased demand, because the 
number of patients requesting these drugs has 
decreased. Although it may be assumed that the 
prescribers control the supply of a drug, the sup-
ply is influenced by persons who feign a painful 
illness to acquire a prescription. A decrease in 
requests by these persons will result in a de-
crease in the number of prescriptions filled. For 
example, studies show that the introduction of a 
less desirable formulation of oxycodone can rap-
idly decrease demand for that formulation.22
Another explanation involves the hundreds of 
programs implemented by local, state, and fed-
eral governments to improve opioid prescribing, 
reduce doctor-shopping, limit questionable prac-
tices by pain clinics, and otherwise improve the 
use of opioid analgesics in the United States.3 In 
addition, other organizations have implemented 
myriad programs such as guidelines for respon-
sible opioid prescribing and educational initia-
tives designed to decrease experimentation. 
Prescription-monitoring programs now operate 
in most states, and early studies indicate their 
effectiveness.23,24 New opioid analgesic formula-
tions that resist tampering have been introduced. 
Finally, law enforcement has intervened success-
fully in some cases, such as closing so-called pill 
mills in Florida.7 It seems plausible that these 
efforts have started to take effect.
The role of switching from the abuse of a 
prescription opioid to the use of high-purity, 
low-cost heroin must also be considered.25 Our 
results support this explanation, as do results 
from the National Survey on Drug Use and 
Health, in which reported use of heroin in the 
previous month increased from 2006 to 2012 
(Fig. 2E).19 The introduction of abuse-deterrent 
OxyContin coincided with a flattening of the 
trajectory of opioid analgesic prescriptions but 
occurred after the increase in reported heroin 
use became apparent. Given that 79.5% of new 
heroin initiates in the National Survey on Drug 
Use and Health reported that their initial drug 
was a prescription opioid and that reported 
heroin use by patients in a substance-abuse pro-
gram nearly doubled after the introduction of 
abuse-deterrent OxyContin, it seems likely that 
the reformulation of extended-release oxycodone 
in 2010 has contributed to the increase in re-
ported heroin use.26,27
Whatever the precise cause, changes in rates 
of opioid analgesic abuse are associated with 
increasing heroin-related mortality. The simi-
larities between data from the National Survey 
on Drug Use and Health and data from the 
National Poison Data System with respect to 
heroin use and adverse consequences are strik-
ing (Fig. 2A and 2E, and Fig. 3). A better 
 understanding of the relation between pre-
scription opioid abuse and heroin use is cru-
cial for developing public health policy as 
well as guiding prevention and treatment initia-
tives.
The largest threat to the validity of our results 
is secular change in the study populations. 
Another concern is methodologic idiosyncrasy 
resulting in a systematic bias toward reduced 
diversion and abuse. We believe these explana-
tions for our findings are unlikely because each 
RADARS program is operated independently by 
separate principal investigators and each ad-
dresses a different aspect of drug abuse. The 
data source, methods, and data management are 
different for each program. We cannot identify 
any programmatic changes that would have cre-
ated an artifactual decrease in reported opioid 
use. Further limitations are described in the 
Supplementary Appendix.
Our results suggest that the United States is 
making progress in combating the abuse of 





































































































Figure 3. Rates of Death Associated with Heroin  
and Prescription Opioids, 2002–2013.
Shown is the rate of death associated with prescription 
opioid drugs (RADARS Poison Center Program) and 
with heroin (National Poison Data System, American 
Association of Poison Control Centers), with adjust-
ment for population.
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tion of decreased abuse is confirmed, changes 
in public health policy and strategy will be 
needed.
Supported by the Denver Health and Hospital Authority.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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